-
Sector Analysis
NewIgA Nephropathy (Berger’s Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Berger's Disease therapeutics. - More than 100,000 incident cases of Berger’s Disease are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for Berger’s Disease. - Pharmacological treatment of Berger's disease involves drugs that help reduce blood pressure and the loss of protein in the urine. - The Berger's disease pipeline consists of over 66 drugs spanning all stages of development. - Over...
-
Product Insights
IgA Nephropathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
IgA Nephropathy Clinical Trials Market Report Overview The IgA Nephropathy clinical trial market research report provides an overview of the IgA Nephropathy clinical trials scenario. The report provides top-line data relating to the clinical trials on IgA Nephropathy. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Product Insights
Nephrotic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in the kidneys that filter waste and excess water from the blood. Its symptoms include severe swelling (edema), foamy urine, and weight gain due to excess fluid retention. The Nephrotic Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of end-stage kidney disease include the inability to urinate, fatigue, headaches, loss of appetite, nausea, vomiting, bone pain, confusion, and concentration difficulties. The End-Stage Kidney Disease pipeline market research report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Urinary Incontinence Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Urinary Incontinence clinical trial market research report provides an overview of the Urinary Incontinence clinical trials scenario. The report provides top-line data relating to the clinical trials on Urinary Incontinence. The Urinary Incontinence, 2022 report includes an overview of trial numbers and their average enrollment in top countries conducted globally. The clinical trials report also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Kidney Disease (Chronic Renal Failure) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue, weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease pipeline drugs market research report provides comprehensive information on the Chronic Renal Failure targeted therapeutics, complete with analysis by indications, stage of...
-
Product Insights
Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis – Drugs In Development, 2022, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include...
-
Product Insights
Overactive Bladder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder – Drugs In Development, 2022, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape. Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge...
-
Product Insights
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glomerulonephritis is a disease of the kidney, characterized by inflammation of the glomeruli. Some factors that increase the chances of getting glomerulonephritis include a family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure. The Glomerulonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers...
-
Sector Analysis
Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Focal segmental glomerulosclerosis market research report includes an assessment of the disease epidemiology, late- to mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Focal segmental glomerulosclerosis (FSGS). The report also analyzes the clinical and commercial landscapes of FSGS, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment. Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury, rather than a single disease, which...
-
Sector Analysis
Chronic Kidney Disease Epidemiology Analysis and Forecast to 2031
The total prevalent cases of chronic kidney disease (CKD) were 103,485,844 cases in 2021 in the 7 major markets (7MM). The number of cases is expected to increase at an annual growth rate (AGR) of more than 1% during the forecast period. Chronic kidney disease or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, chronic...
-
Product Insights
IgA Nephropathy (Bergers Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
IgA Nephropathy (Berger's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Focal Segmental Glomerulosclerosis (FSGS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
-
Product Insights
Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Stress Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Stress Urinary Incontinence, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news...
-
Product Insights
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action...
-
Product Insights
Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Membranous Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
-
Product Insights
Primary Hyperoxaluria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Primary Hyperoxaluria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
-
Product Insights
Primary Hyperoxaluria Type I Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Primary Hyperoxaluria Type I Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary Hyperoxaluria Type I pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria Type I, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
-
Product Insights
Interstitial Cystitis (Painful Bladder Syndrome-Bladder Pain Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action...
-
Product Insights
Renal Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Renal Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Renal Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Renal Failure, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.